$1.24
6.06% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US19249H1032
Symbol
CHRS
Sector
Industry

Coherus BioSciences, Inc. Stock price

$1.24
-0.09 6.77% 1M
-0.97 43.89% 6M
-2.09 62.76% YTD
-3.74 75.10% 1Y
-14.46 92.10% 3Y
-19.22 93.94% 5Y
-11.37 90.17% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.08 6.06%
ISIN
US19249H1032
Symbol
CHRS
Sector
Industry

Key metrics

Market capitalization $142.86m
Enterprise Value $281.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.92
P/S ratio (TTM) P/S ratio 0.46
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 69.37%
Revenue (TTM) Revenue $308.13m
EBIT (operating result TTM) EBIT $-156.60m
Free Cash Flow (TTM) Free Cash Flow $-54.30m
Cash position $159.24m
EPS (TTM) EPS $-0.41
P/E forward 2.91
P/S forward 0.53
EV/Sales forward 1.04
Short interest 24.32%
Show more

Is Coherus BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Coherus BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Coherus BioSciences, Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Coherus BioSciences, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Coherus BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
308 308
69% 69%
100%
- Direct Costs 186 186
97% 97%
60%
123 123
39% 39%
40%
- Selling and Administrative Expenses 177 177
7% 7%
57%
- Research and Development Expense 97 97
25% 25%
31%
-151 -151
34% 34%
-49%
- Depreciation and Amortization 5.39 5.39
43% 43%
2%
EBIT (Operating Income) EBIT -157 -157
33% 33%
-51%
Net Profit -29 -29
89% 89%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Coherus BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coherus BioSciences, Inc. Stock News

Positive
Seeking Alpha
25 days ago
Coherus BioSciences, Inc. focuses on biosimilars and immuno-oncology treatments, with LOQTORZI and UDENYCA as key products. Coherus BioSciences' biosimilar IP shows potential for profitability, with strategic divestitures impacting its financial position post Q3 2024. UDENYCA drives most of CHRS's revenues, positioning it as its crown jewel with a 29% market share and strong payer coverage.
Neutral
Seeking Alpha
29 days ago
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Jami Taylor - Head of Investor Relations Dennis Lanfear - President and Chief Executive Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer Bryan McMichael - Chief Financial Officer Conference Call Part...
Neutral
GlobeNewsWire
about one month ago
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general ...
More Coherus BioSciences, Inc. News

Company Profile

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Head office United States
CEO Denny Lanfear
Employees 306
Founded 2010
Website www.coherus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today